Search Results - "Rubio, María Jesus"

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial by Trigo, José, Subbiah, Vivek, Besse, Benjamin, Moreno, Victor, López, Rafael, Sala, María Angeles, Peters, Solange, Ponce, Santiago, Fernández, Cristian, Alfaro, Vicente, Gómez, Javier, Kahatt, Carmen, Zeaiter, Ali, Zaman, Khalil, Boni, Valentina, Arrondeau, Jennifer, Martínez, Maite, Delord, Jean-Pierre, Awada, Ahmad, Kristeleit, Rebecca, Olmedo, Maria Eugenia, Wannesson, Luciano, Valdivia, Javier, Rubio, María Jesús, Anton, Antonio, Sarantopoulos, John, Chawla, Sant P, Mosquera-Martinez, Joaquín, D'Arcangelo, Manolo, Santoro, Armando, Villalobos, Victor M, Sands, Jacob, Paz-Ares, Luis

“…Few options exist for treatment of patients with small-cell lung cancer (SCLC) after failure of first-line therapy. Lurbinectedin is a selective inhibitor of…”
Get full text

Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer by Herzog, Thomas J., Pignata, Sandro, Ghamande, Sharad A., Rubio, Maria-Jesús, Fujiwara, Keiichi, Vulsteke, Christof, Armstrong, Deborah K., Sehouli, Jalid, Coleman, Robert L., Gabra, Hani, Scambia, Giovanni, Monk, Bradley J., Arranz, José A., Ushijima, Kimio, Hanna, Rabbie, Zamagni, Claudio, Wenham, Robert M., González-Martín, Antionio, Slomovitz, Brian, Jia, Yan, Ramsay, Lisa, Tewari, Krishnansu S., Weil, Susan C., Vergote, Ignace B.

“…The primary purpose of this study was to determine if farletuzumab, an antifolate receptor-α monoclonal antibody, improved progression-free survival (PFS)…”
Get full text

Retrospective multicenter study of elderly patients with platinum-sensitive relapsed ovarian cancer treated with trabectedin and pegylated liposomal doxorubicin (pld) in a real-world setting: a geico study by Rubio, María Jesús, Manzano, Aránzazu, de Sande, Luis Miguel, Estévez-García, Purificación, Gordon, María Del Mar, de Prado, Diego Soto, de Aranguiz, Blanca Hernando Fernández, Guerra-Alia, Eva M, Carbó-Bagué, Anna, Romero, Ignacio, Corbellas, Miguel, González-Haba, Alba, Robles-Barraza, Carlos E, Martínez-García, Jerónimo, González-Martín, Antonio

“…Trabectedin in combination with pegylated liposomal doxorubicin (PLD) is approved for the treatment of patients with platinum-sensitive relapsed ovarian…”
Get full text

Impact of the historical introduction of exotic fishes on the chironomid community of Lake Azul (Azores Islands) by Raposeiro, Pedro Miguel, Rubio, Maria Jesus, González, Alba, Hernández, Armand, Sánchez-López, Guiomar, Vázquez-Loureiro, David, Rull, Valentí, Bao, Roberto, Costa, Ana Cristina, Gonçalves, Vítor, Sáez, Alberto, Giralt, Santiago

“…Little is known about the effect of top predator introduction in historically fishless communities, especially on remote islands. This issue is important…”
Get full text

Controversies in the treatment of advanced ovarian cancer in the PARP inhibitors era: a Delphi consensus by Redondo, Andrés, Barretina, Pilar, Pérez-Fidalgo, Alejandro, Rubio, María Jesús, González-Martín, Antonio

“…Our aim was to reach a consensus on the management of the most controversial issues of advanced ovarian cancer. Nominal group and Delphi techniques were used…”
Get full text

Effect of the Combination of Trabectedin and Pegylated Liposomal Doxorubicin in a BRCA2 Mutation Carrier with Recurrent Platinum-Sensitive Ovarian Cancer by Rubio Pérez, María Jesús 

“…Introduction: The current standard of care for ovarian cancer is optimal cytoreduction with adjuvant chemotherapy based on a platinum/taxane combination…”
Get full text

Efficacy and safety of trabectedin in metastatic uterine leiomyosarcoma: A retrospective multicenter study of the Spanish ovarian cancer research group (GEICO) by Rubio, María Jesús, Lecumberri, María José, Varela, Silvia, Alarcón, Jesús, Ortega, María Eugenia, Gaba, Lydia, Espinós, Jaime, Calzas, Julia, Barretina, Pilar, Ruiz, Isabel, Marquina, Gloria, Santaballa, Ana

“…•Trabectedin confers clinical benefit in patients with recurrent/metastatic uterine leiomyosarcoma.•Our data are similar to those previously reported in…”
Get full text

A Unified Convergence Analysis for Some Two-Point Type Methods for Nonsmooth Operators by Amat, Sergio, Argyros, Ioannis, Busquier, Sonia, Hernández-Verón, Miguel Ángel, Rubio, María Jesús

“…The aim of this paper is the approximation of nonlinear equations using iterative methods. We present a unified convergence analysis for some two-point type…”
Get full text

SEOM-GEICO clinical guidelines on endometrial cancer (2021) by Barretina-Ginesta, María Pilar, Quindós, María, Alarcón, Jesús Damián, Esteban, Carmen, Gaba, Lydia, Gómez, César, Fidalgo, José Alejandro Pérez, Romero, Ignacio, Santaballa, Ana, Rubio-Pérez, María Jesús

“…Endometrial cancer (EC) is the second most common gynecological malignancy worldwide, the first in developed countries [Sung et al. in CA Cancer J Clin…”
Get full text

Vegetation and landscape dynamics under natural and anthropogenic forcing on the Azores Islands: A 700-year pollen record from the São Miguel Island by Rull, Valentí, Lara, Arantza, Rubio-Inglés, María Jesús, Giralt, Santiago, Gonçalves, Vítor, Raposeiro, Pedro, Hernández, Armand, Sánchez-López, Guiomar, Vázquez-Loureiro, David, Bao, Roberto, Masqué, Pere, Sáez, Alberto

“…The Azores archipelago has provided significant clues to the ecological, biogeographic and evolutionary knowledge of oceanic islands. Palaeoecological records…”
Get full text

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial by Gladieff, Laurence, Martínez-García, Jerónimo, Villacampa, Guillermo, Takekuma, Munetaka, De Giorgi, Ugo, Lindemann, Kristina, Woelber, Linn, Colombo, Nicoletta, Duska, Linda, Leary, Alexandra, Godoy-Ortiz, Ana, Angelergues, Antoine, Rubio, Maria Jesús, Fariñas-Madrid, Lorena, Lorusso, Domenica, Ray-Coquard, Isabelle, Manso, Luis, Joly, Florence, Alarcón, Jesús, Follana, Philippe, Romero, Ignacio, Lebreton, Coriolan, Pérez-Fidalgo, J Alejandro, Yunokawa, Mayu, Dahlstrand, Hanna, Abadie-Lacourtoisie, Sophie, Anzizar, Nerea, Aoki, Daiseuke, Barretina-Ginesta, Maria-Pilar, Battista, Marco, Bentzen, Anne Gry, Berton, Dominique, Bjørge, Line, Bjurberg, Maria, Bologna, Alessandra, Casanova, Claudia, Chekerov, Radoslav, Chevalier, Annick, Cueva, Juan Fernando, Czogalla, Bastian, Delanoy, Nicolas, Denschlag, Dominik, Derke, Oscar, Eichbaum, Michael, Enomoto, Takayuki, Esteban, Carmen, Fabbro, Michel, Fehm, Tanja, Ferrero, Annamaria, Fleisch, Markus, Floquet, Anne, Frassoldati, Antonio, Gaba, Lydia, Gadducci, Angiolo, García, Yolanda, Geuna, Elena, Hanker, Lars, Hardy-Bessard, Anne-Claire, Harter, Philipp, Hasegawa, Kosei, Hellman, Kristina, Herrero, Ana, Hilpert, Felix, Katsaros, Dionyssios, Koegel, Matthias, Koliadi, Anthoula, Kurtz, Jean-Emmanuel, Lampe, Bjoern, Lissoni, Andrea Alberto, Lortholary, Alain, Mangili, Giorgia, Mansi, Laura, Marmé, Frederik, Mathews, Cara, Mina, William, Nagao, Shoji, Nishino, Koji, Nishio, Hiroshi, Nishio, Shin, Oaknin, Ana, Onstad, Michaela, Pardo, Beatriz, Pisano, Carmela, Poveda, Andrés, Radosa, Julia, Randall, Leslie M., Ray-Coquard, Isabelle, Richardson, Debra, Romero, Ignacio, Ronzino, Graziana, Rubio, Maria Jesús, Selle, Frederic, Takekuma, Munetaka, Takeshima, Nobuhiro, Tewari, Krishnansu, Todo, Yukiharu, Wimberger, Pauline, Woelber, Linn, You, Benoît, Yunokawa, Mayu

“…The GOG240 trial established bevacizumab with chemotherapy as standard first-line therapy for metastatic or recurrent cervical cancer. In the BEATcc trial…”
Get full text

Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study) by Tavira, Beatriz, Iscar, Teresa, Manso, Luis, Santaballa, Ana, Gil-Martin, Marta, García García, Yolanda, Romeo, Margarita, Iglesias, Maria, de Juan Ferré, Ana, Barretina-Ginesta, María Pilar, Manzano, Aranzazu, Gaba, Lydia, Rubio, María Jesús, de Andrea, Carlos E, González-Martín, Antonio

“…The aim of our study was to elucidate the impact of bevacizumab added to neoadjuvant chemotherapy (NACT) on the tumor immune microenvironment and correlate the…”
Get full text

Climate change facilitated the early colonization of the Azores Archipelago during medieval times by Raposeiro, Pedro M., Hernández, Armand, Pla-Rabes, Sergi, Gonçalves, Vítor, Bao, Roberto, Sáez, Alberto, Shanahan, Timothy, Benavente, Mario, de Boer, Erik J., Richter, Nora, Gordon, Verónica, Marques, Helena, Sousa, Pedro M., Souto, Martín, Matias, Miguel G., Aguiar, Nicole, Pereira, Cátia, Ritter, Catarina, Rubio, María Jesús, Salcedo, Marina, Vázquez-Loureiro, David, Margalef, Olga, Amaral-Zettler, Linda A., Costa, Ana Cristina, Huang, Yongsong, van Leeuwen, Jacqueline F. N., Masqué, Pere, Prego, Ricardo, Ruiz-Fernández, Ana Carolina, Sanchez-Cabeza, Joan-Albert, Trigo, Ricardo, Giralt, Santiago

“…Humans have made such dramatic and permanent changes to Earth’s landscapes that much of it is now substantially and irreversibly altered from its…”
Get full text

Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment by Subbiah, Vivek, Paz-Ares, Luis, Besse, Benjamin, Moreno, Victor, Peters, Solange, Sala, María Angeles, López-Vilariño, José Antonio, Fernández, Cristian, Kahatt, Carmen, Alfaro, Vicente, Siguero, Mariano, Zeaiter, Ali, Zaman, Khalil, López, Rafael, Ponce, Santiago, Boni, Valentina, Arrondeau, Jennifer, Delord, Jean-Pierre, Martínez, Maite, Wannesson, Luciano, Antón, Antonio, Valdivia, Javier, Awada, Ahmad, Kristeleit, Rebecca, Olmedo, Maria Eugenia, Rubio, María Jesús, Sarantopoulos, John, Chawla, Sant P., Mosquera-Martinez, Joaquín, D’ Arcangelo, Manolo, Santoro, Armando, Villalobos, Victor M., Sands, Jacob, Trigo, José

“…•The NCCN recommends first-line re-challenge for relapsed SCLC with CTFI ≥ 180 days.•This recommendation is based on data from small trials from the…”
Get full text

Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer by Garcia Garcia, Yolanda, de Juan Ferré, Ana, Mendiola, Cesar, Barretina-Ginesta, Maria-Pilar, Gaba Garcia, Lydia, Santaballa Bertrán, Ana, Bover Barcelo, Isabel, Gil-Martin, Marta, Manzano, Aranzazu, Rubio Pérez, Maria Jesús, Romeo Marin, Margarita, Arqueros Núñez, Cristina, García-Martínez, Elena, Gonzalez Martin, Antonio

“…Bevacizumab is an approved treatment after primary debulking surgery for ovarian cancer. However, there is limited information on bevacizumab added to…”
Get more information

Reply to Elias et al.: Multiproxy evidence of widespread landscape disturbance in multiple Azorean lakes before the Portuguese arrival by Raposeiro, Pedro M, Hernández, Armand, Pla-Rabes, Sergi, Gonçalves, Vítor, Bao, Roberto, Sáez, Alberto, Shanahan, Timothy, Benavente, Mario, de Boer, Erik J, Richter, Nora, Gordon, Verónica, Marques, Helena, Sousa, Pedro M, Souto, Martín, Matias, Miguel G, Aguiar, Nicole, Pereira, Cátia, Ritter, Catarina, Rubio, María Jesús, Salcedo, Marina, Vázquez-Loureiro, David, Margalef, Olga, Amaral-Zettler, Linda A, Costa, Ana Cristina, Huang, Yongsong, van Leeuwen, Jacqueline F N, Masqué, Pere, Prego, Ricardo, Ruiz-Fernández, Ana Carolina, Sanchez-Cabeza, Joan-Albert, Trigo, Ricardo, Giralt, Santiago

Get full text

Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study by Poveda, Andres, Lopez-Reig, Raquel, Oaknin, Ana, Redondo, Andres, Rubio, Maria Jesus, Guerra, Eva, Fariñas-Madrid, Lorena, Gallego, Alejandro, Rodriguez-Freixinos, Victor, Fernandez-Serra, Antonio, Juan, Oscar, Romero, Ignacio, Lopez-Guerrero, Jose A

“…We hypothesized that the combination of olaparib and lurbinectedin maximizes DNA damage, thus increasing its efficacy. The POLA phase 1 trial established the…”
Get full text

Prospective Real-World Gynaecological Cancer Clinical Registry with Associated Biospecimens: A Collaborative Model to Promote Translational Research between GEICO and the Spanish Biobank Network by López-Guerrero, José Antonio, Mendiola, Marta, Pérez-Fidalgo, José Alejandro, Romero, Ignacio, Torres, Ana, Recalde, Delia, Molina, Elena, Gómez-Raposo, César, Levin, Ana M, Herrero, Ana, Alarcón, Jesús, Esteban, Carmen, Marquina, Gloria, Rubio, María Jesús, Guerra, Eva, Sánchez-Lorenzo, Luisa, Gálvez-Montosa, Fernando, de Juan, Ana, Churruca, Cristina, Gallego, Alejandro, González-Martín, Antonio

“…Patient registries linked to biorepositories constitute a valuable asset for clinical and translational research in oncology. The Spanish Group of Ovarian…”
Get full text

Management of advanced ovarian cancer in Spain: an expert Delphi consensus by Redondo, Andres, Oaknin, Ana, Rubio, Maria Jesus, Barretina-Ginesta, Maria-Pilar, de Juan, Ana, Manso, Luis, Romero, Ignacio, Martin-Lorente, Cristina, Poveda, Andres, Gonzalez-Martin, Antonio

“…To determine the state of current practice and to reach a consensus on recommendations for the management of advanced ovarian cancer using a Delphi survey with…”
Get full text

A phase II trial of fixed-dosed rate gemcitabine in platinum-resistant ovarian cancer: a GEICO (Grupo Español de Investigación en Cáncer de Ovario) Trial by Ojeda Gonzalez, Belen, Gonzalez Martin, Antonio, Bover Barcelo, Isabel, Fabregat i Mayol, Xavier, Mellado, Begoña, Rubio Perez, María Jesus, Alonso Carrion, Lorenzo, Casado Herraez, Antonio, Calvo Garcia, Elisa, Churruca Galaz, Cristina, Arcusa Lanza, Angels, Herrero Ibañez, Ana, Adrover Cebrian, Encarna, Poveda Velasco, Andres

“…Gemcitabine has well-recognized activity in the treatment of ovarian cancer. Fixed-dose rate (FDR) delivery has been proposed as a more rationale way to…”
Get full text